Stereotactic Body Radiotherapy and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer: Single Arm Phase 2...

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Locally advanced non-small cell lung cancer (NSCLC) presents significant treatment challenges.
• Current treatment paradigms for unresectable stage 2 and 3 NSCLC require effective and tolerable therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with full-dose systemic chemotherapy for unresectable stage 2 and 3 NSCLC.
• To assess disease-free survival and toxicity profiles of this combined treatment approach.

Main Methods:

• A single-arm, phase 2 clinical trial (NCT02568033) involving 22 patients with unresectable stage 2/3 NSCLC.
• SBRT delivered to gross disease sites with specific fractionation for lung tumors and lymph nodes, concurrent with 4 cycles of chemotherapy (pemetrexed/cisplatin or carboplatin/paclitaxel for nonsquamous; cisplatin/docetaxel or paclitaxel for squamous).
• Quality of life assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire.

Main Results:

• Median overall survival of 27.2 months, with 1-year and 2-year survival rates of 82% and 53%, respectively.
• Median disease-free survival of 16.0 months; 2-year regional failure rate of 19% and distant failure rate of 47.2%.
• Six grade 3 acute toxicities and two late grade 3+ toxicities (including one fatal hemoptysis); quality of life scores remained stable.

Conclusions:

• The combination of SBRT and full-dose chemotherapy is a safe and effective treatment option for locally advanced NSCLC.
• This combined modality treatment demonstrates promising survival outcomes and warrants further investigation in larger trials.